In patients with dystrophinopathy, CK-adjusted ALT diminished the variability associated with age, genotype, clinical phenotype, and motor function (P > 0.05). This evidence concerns the gene GPT and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.